Advertisement
Screener

REGENERON PHARMACEUTICALS, INC. (REGN) Graph

REGN Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $4.29B; Research and development $1.63B; Selling, general and administrative $662.10M; Income tax $230.90M.
  • 2026-03-31: Revenue $3.61B; Research and development $1.54B; Selling, general and administrative $647.70M; Income tax $104.00M.
  • 2025-12-31: Revenue $3.88B*; Research and development $1.63B*; Selling, general and administrative $775.00M*; Income tax $199.10M*.
  • 2025-09-30: Revenue $3.75B; Research and development $1.48B; Selling, general and administrative $657.80M; Income tax $303.30M.

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

REGN revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Product AndService Other$193.30MProduct$1.64BCollaboration Revenue$2.46BLIBTAYO NetProduct Sales$489.40MLynozyfic$16.50MOther Products$0.00Revenue$4.29BOperating income$1.29BOther income, net$245.30MResearch & development$1.63BSelling, general& administrative$662.10MPre-tax income$1.53BIncome tax$230.90MNet income$1.30B

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentSelling, general and administrativeIncome taxNet income
2026-06-30$4.29B$1.63B$662.10M$230.90M$1.30B
2026-03-31$3.61B$1.54B$647.70M$104.00M$727.20M
2025-12-31$3.88B*$1.63B*$775.00M*$199.10M*$844.60M*
2025-09-30$3.75B$1.48B$657.80M$303.30M$1.46B
2025-06-30$3.68B$1.42B$634.20M$127.10M$1.39B
2025-03-31$3.03B$1.33B$633.00M$96.30M$808.70M
2024-09-30$3.72B$1.27B$714.40M$152.40M$1.34B
2024-06-30$3.55B$1.20B$758.80M$195.80M$1.43B
2024-03-31$3.15B$1.25B$689.00M-$21.30M$722.00M
2023-09-30$3.36B$1.08B$640.50M$103.00M$1.01B
2023-06-30$3.16B$1.09B$652.00M$114.50M$968.40M
2023-03-31$3.16B$1.10B$601.10M$40.20M$817.80M
2022-09-30$2.94B$911.30M$529.10M$194.10M$1.32B
2022-06-30$2.86B$794.30M$476.30M$111.10M$852.10M
2022-03-31$2.97B$843.80M$450.00M$87.60M$973.50M
2021-09-30$3.45B$665.40M$445.00M$184.40M$1.63B
2021-06-30$5.14B$714.20M$414.70M$653.90M$3.10B
2021-03-31$2.53B$742.90M$405.60M$137.80M$1.12B
2020-12-31$2.42B(m)(m)(m)$1.15B
2020-09-30$2.29B$684.60M$326.90M$156.20M$842.10M
2020-06-30$1.95B$722.00M$348.30M$21.60M$897.30M
2020-03-31$1.83B$583.90M$367.30M$44.00M$624.60M
2019-12-31$1.86B(m)(m)(m)$792.00M
2019-09-30$1.74B$526.00M$304.40M$98.90M$669.60M
2019-06-30$1.58B$885.50M$294.60M$31.60M$193.10M
2019-03-31$1.37B$486.10M$291.10M$85.00M$461.10M
2018-12-31$1.93B(m)(m)(m)$820.40M
2018-09-30$1.66B$557.00M$369.20M$41.20M$594.70M
2018-06-30$1.61B$529.30M$364.80M$104.70M$551.40M
2018-03-31$1.51B$498.60M$330.80M$107.40M$478.00M
2017-12-31$1.58B(m)(m)(m)$173.50M
2017-09-30$1.50B$529.75M$306.77M$177.29M$388.30M
2017-06-30$1.47B$509.98M$306.91M$138.11M$387.70M
2017-03-31$1.32B$507.44M$296.85M$183.36M$248.90M
2016-12-31$1.23B(m)(m)(m)$253.12M
2016-09-30$1.22B$543.05M$270.05M$101.08M$264.80M
2016-06-30$1.21B$559.93M$292.04M$96.04M$196.22M
2016-03-31$1.20B$470.11M$289.68M$148.77M$181.38M
2015-12-31$1.10B(m)(m)(m)$154.99M
2015-09-30$1.14B$425.92M$209.99M$182.89M$210.40M
2015-06-30$998.62M$390.33M$174.59M$133.35M$194.64M
2015-03-31$869.61M$343.11M$158.99M$200.50M$76.02M
2014-12-31$802.33M(m)$175.31M$99.63M$90.09M
2014-09-30$725.79M$337.73M$144.00M$98.45M$83.38M
2014-06-30$665.70M$294.50M$96.73M$112.45M$96.35M
2014-03-31$625.74M$287.38M$103.23M$112.58M$68.31M
2013-12-31$610.41M(m)(m)(m)$96.81M
2013-09-30$597.03M$224.04M$97.61M$84.38M$141.31M
2013-06-30$457.64M$187.46M$72.46M$60.32M$87.38M
2013-03-31$439.66M$180.30M$77.26M$42.96M$98.87M
2012-12-31$414.60M(m)(m)-$335.80M$470.41M
2012-09-30$427.69M$158.29M$46.88M(m)$191.47M
2012-06-30$304.40M$147.37M$47.70M$0.00$76.74M
2012-03-31$231.79M$138.86M$58.43M(m)$11.65M
2011-12-31$122.98M(m)(m)(m)-$53.44M
2011-09-30$102.83M$127.92M$32.92M$562.00K-$62.37M
2011-06-30$107.81M$143.15M$24.59M-$863.00K-$62.51M
2011-03-31$112.20M$129.39M$23.41M-$216.00K-$43.45M
2010-12-31$133.68M(m)(m)(m)-$14.60M
2010-09-30$105.98M$122.04M$15.66M$0.00-$33.88M
2010-06-30$115.89M$124.53M$14.68M$0.00-$25.47M
2010-03-31$103.53M$117.47M$14.22M$0.00-$30.52M
2009-09-30$117.45M$105.43M$12.84M(m)-$1.01M
2009-06-30$90.03M$94.23M$11.63M(m)-$14.94M

Revenue and expense 6 month

Period endRevenueResearch and developmentSelling, general and administrativeIncome taxNet income
2026-06-30$7.90B$3.18B$1.31B$334.90M$2.02B
2025-06-30$6.70B$2.75B$1.27B$223.40M$2.20B
2024-06-30$6.69B$2.45B$1.45B$174.50M$2.15B
2023-06-30$6.32B$2.19B$1.25B$154.70M$1.79B
2022-06-30$5.82B$1.64B$926.30M$198.70M$1.83B
2021-06-30$7.67B$1.46B$820.30M$791.70M$4.21B
2020-06-30$3.78B$1.31B$715.60M$65.60M$1.52B
2019-06-30$2.95B$1.37B$585.70M$116.60M$654.20M
2018-06-30$3.12B$1.03B$695.60M$212.10M$1.03B
2017-06-30$2.79B$1.02B$603.75M$321.46M$636.67M
2016-06-30$2.41B$1.03B$581.72M$244.80M$377.60M
2015-06-30$1.87B$733.44M$333.58M$333.86M$270.66M
2014-06-30$1.29B$581.88M$199.96M$225.03M$164.66M
2013-06-30$897.31M$367.76M$149.72M$103.27M$186.25M
2012-06-30$536.19M$286.24M$106.13M$0.00$88.39M
2011-06-30$220.01M$272.54M$48.00M-$1.08M-$105.95M
2010-06-30$219.42M$242.00M$28.90M$0.00-$56.00M
2009-06-30$165.01M$174.54M$23.05M(m)-$30.33M

Revenue and expense 9 month

Period endRevenueResearch and developmentSelling, general and administrativeIncome taxNet income
2025-09-30$10.46B$4.22B$1.93B$526.70M$3.66B
2024-09-30$10.41B$3.72B$2.16B$326.90M$3.49B
2023-09-30$9.68B$3.26B$1.89B$257.70M$2.79B
2022-09-30$8.76B$2.55B$1.46B$392.80M$3.14B
2021-09-30$11.12B$2.12B$1.27B$976.10M$5.85B
2020-09-30$6.07B$1.99B$1.04B$221.80M$2.36B
2019-09-30$4.69B$1.90B$890.10M$215.50M$1.32B
2018-09-30$4.78B$1.58B$1.06B$253.30M$1.62B
2017-09-30$4.29B$1.55B$910.52M$498.75M$1.02B
2016-09-30$3.63B$1.57B$851.76M$345.88M$642.41M
2015-09-30$3.01B$1.16B$543.57M$516.75M$481.06M
2014-09-30$2.02B$919.61M$343.96M$323.48M$248.03M
2013-09-30$1.49B$591.81M$247.33M$187.65M$327.56M
2012-09-30$963.88M$444.53M$153.02M(m)$279.86M
2011-09-30$322.85M$400.46M$80.91M-$517.00K-$168.32M
2010-09-30$325.40M$364.04M$44.56M$0.00-$89.87M
2009-09-30$282.47M$279.97M$35.89M(m)-$31.34M

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeIncome taxNet income
2025-12-31$14.34B(m)$5.85B$2.70B$725.80M$4.50B
2024-12-31$14.20B(m)$5.13B$2.95B$367.30M$4.41B
2023-12-31$13.12B(m)$4.44B$2.63B$245.70M$3.95B
2022-12-31$12.17B(m)$3.59B$2.12B$520.40M$4.34B
2021-12-31$16.07B(m)$2.86B$1.82B$1.25B$8.08B
2020-12-31$8.50B(m)$2.65B$1.35B$297.20M$3.51B
2019-12-31$6.56B$402.80M$2.45B$1.34B$313.30M$2.12B
2018-12-31$5.15B$237.50M$1.47B$1.13B$109.10M$2.44B
2017-12-31$5.87B(m)$2.08B$1.32B$880.00M$1.20B
2016-12-31$4.86B(m)$2.05B$1.18B$434.30M$895.50M
2015-12-31$4.10B(m)$1.62B$838.53M$589.04M$636.06M
2014-12-31$2.82B(m)$1.27B$519.27M$423.11M$338.13M
2013-12-31$2.10B(m)$859.95M$346.39M$282.64M$413.74M
2012-12-31$1.38B(m)$625.55M$210.75M-$335.85M$750.27M
2011-12-31$445.82M(m)$529.51M$117.26M-$1.13M-$221.76M
2010-12-31$459.07M(m)$489.25M$65.20M$0.00-$104.47M
2009-12-31$379.27M(m)$398.76M$52.92M-$4.12M-$67.83M
2008-12-31$238.46M(m)$274.90M$48.88M$2.35M-$79.13M

Similar stocks

Stock NameCountryMarket CapPE Ratio
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Zoetis Inc. (ZTS)United States$29.045B11.38
INSMED Inc (INSM)United States$26.566B-26.60
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
BRISTOL MYERS SQUIBB CO (BMY)United States$125.637B12.67
Royalty Pharma plc (RPRX)United States$22.628B
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64
Viatris Inc (VTRS)United States$20.008B-0.00
VERTEX PHARMACEUTICALS INC / MA (VRTX)United States$132.481B28.56
Jazz Pharmaceuticals plc (JAZZ)$15.333B16.07